Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Loxo Oncology, Inc.
Jeff P Sharman; Talha Munir; Sebastian Grosicki; Lindsey E Roeker; John M Burke; Christine I Chen; Norbert Grzasko; George Follows; Zoltán Mátrai; Alessandro Sanna; Lugui Qiu; Ru Feng; Vu Minh Hua; Wojciech Jurczak; Matthias Ritgen; Shuhua Yi; Francesc Bosch; Catherine C Coombs; Katherine Bao; Vishalkumar Patel; Bin Liu; Livia Compte; Ananya Guntur; Denise Y Wang; Marisa Hill; Ching Ching Leow; Paolo Ghia; Paul M Barr